

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.300; Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Aurobindo Pharma (ribavirin) • Merck Sharp & Dohme (peginterferon alfa 2b, ribavirin) • Roche Products (peginterferon alfa 2a, ribavirin) • Teva UK (ribavirin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Action on Addiction • Addaction • Addiction today • ADFAM • African Health Policy Network (AHPN) • Alcohol and Drugs Action (ADA) • Black Health Agency • British Liver Trust • Children's Liver Disease Foundation • Compass UK • Contact a Family • GMFA - The Gay Men's Health Charity • Haemophilia Alliance • Haemophilia Society • Hepatitis C Trust • HIV i-Base • Liver 4 Life • Muslim Council of Britain • NAM publications • National AIDS Trust • National Children's Bureau • Positively UK • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • Alcohol and Drugs Action (Scotland) • Allied Health Professionals Federation • Association of British Healthcare Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • EUCOMED • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Aurobindo Pharma (ribavirin) • Merck Sharp & Dohme (peginterferon alfa 2b, ribavirin) • Roche Products (peginterferon alfa 2a, ribavirin) • Teva UK (ribavirin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Cochrane Infectious Diseases Group • Foundation for Liver Research • MRC Clinical Trials Unit • National Institute for Health Research

<ul style="list-style-type: none"> • UK Harm Reduction Alliance • United Kingdom Thalassaemia Society <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Clinical Biochemists - Microbiology Section • British Association for Sexual Health and HIV • British Geriatrics Society • British Association for the Study of the Liver • British HIV Association • British Infection Association • British Liver Nurses Forum • British Society of Gastroenterology • British Transplantation Society • British Viral Hepatitis Group • ESPRIT • Haemophilia Nurses Association • HCV Action • Hepatitis Nurse Specialist Forum • Infection Prevention Society • Medical Foundation for AIDS & Sexual Health • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for General Microbiology • UK Clinical Pharmacy Association • UK Clinical Virology Network • UK Haemophilia Centre Doctors' Organisation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Corby CCG • NHS England • NHS Erewash CCG • Welsh Government 	<ul style="list-style-type: none"> • UCL Centre for Sexual Health & HIV Research • UK National Screening Committee <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.